William Blair Issues Negative Outlook for Amedisys Earnings

Amedisys, Inc. (NASDAQ:AMED) – Research analysts at William Blair dropped their Q2 2025 earnings per share estimates for shares of Amedisys in a research report issued on Thursday, April 24th. William Blair analyst M. Larew now anticipates that the health services provider will post earnings per share of $1.32 for the quarter, down from their prior estimate of $1.33. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share.

AMED has been the topic of a number of other research reports. Stephens reissued an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Amedisys currently has a consensus rating of “Hold” and an average price target of $100.75.

Amedisys Trading Up 0.7 %

Shares of Amedisys stock opened at $94.27 on Friday. Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market cap of $3.09 billion, a P/E ratio of 37.41, a P/E/G ratio of 1.78 and a beta of 0.89. The stock’s 50 day simple moving average is $92.17 and its 200-day simple moving average is $91.83.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million.

Institutional Trading of Amedisys

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Trexquant Investment LP boosted its position in shares of Amedisys by 1,317.8% during the fourth quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider’s stock worth $7,964,000 after buying an additional 81,532 shares during the period. ABC Arbitrage SA acquired a new position in shares of Amedisys during the fourth quarter worth about $2,522,000. Oddo BHF Asset Management Sas acquired a new position in Amedisys during the 3rd quarter worth approximately $7,238,000. Empowered Funds LLC purchased a new stake in shares of Amedisys during the 4th quarter worth $318,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Amedisys in the fourth quarter valued at $590,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.